Quốc gia: Hoa Kỳ
Ngôn ngữ: Tiếng Anh
Nguồn: NLM (National Library of Medicine)
POTASSIUM CHLORIDE (UNII: 660YQ98I10) (POTASSIUM CATION - UNII:295O53K152)
Lupin Pharmaceuticals, Inc.
POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 10 meq
ORAL
PRESCRIPTION DRUG
Potassium chloride extended-release capsules are indicated for the treatment and prophylaxis of hypokalemia in adults and children with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. Potassium chloride extended-release capsules are contraindicated in patients on amiloride or triamterene. Risk Summary There are no human data related to use of potassium chloride extended-release capsules during pregnancy and animal reproductive studies have not been conducted. Potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. The background risk for major birth defects and miscarriage in the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respecti
Potassium chloride Extended-Release Capsules USP contain 600 mg and 750 mg of potassium chloride (equivalent to 8 mEq and 10 mEq of potassium, respectively). Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59° to 86°F) [See USP Controlled Room Temperature] . Dispense in tight, light-resistant container as defined in the USP, with a child-resistant closure. Rx only
Abbreviated New Drug Application
POTASSIUM CHLORIDE- POTASSIUM CHLORIDE CAPSULE, COATED, EXTENDED RELEASE LUPIN PHARMACEUTICALS, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE POTASSIUM CHLORIDE EXTENDED-RELEASE CAPSULES SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR POTASSIUM CHLORIDE EXTENDED-RELEASE CAPSULES POTASSIUM CHLORIDE EXTENDED-RELEASE CAPSULES FOR ORAL ADMINISTRATION INITIAL U.S. APPROVAL: 1948 INDICATIONS AND USAGE Potassium chloride extended-release capsules, USP contain potassium chloride, a potassium salt indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.(1) DOSAGE AND ADMINISTRATION Monitor serum potassium and adjust dosage accordingly (2.1) If serum potassium concentration is <2.5 mEq/L, use intravenous potassium instead of oral supplementation.(2.1) _Treatment of hypokalemia_: Adults: Typical doses range from 40 to 100 mEq/day in 2 to 5 divided doses; limit doses to 40 mEq per dose.(2.2) Pediatric patients: 2 to 4 mEq/kg/day in divided doses not to exceed 1 mEq/kg as a single dose or 20 mEq, whichever is lower; if deficits are severe or ongoing losses are great, consider intravenous therapy.(2.3) _Maintenance or Prophylaxis of hypokalemia_: Adults: Typical dose is 20 mEq per day (2.2) Pediatric patients: Typical dose is 1 mEq/kg/day.(2.3) DOSAGE FORMS AND STRENGTHS Extended-release capsules: 600 mg (8mEq) and 750 mg (10 mEq) CONTRAINDICATIONS Concomitant use with triamterene and amiloride.(4) WARNINGS AND PRECAUTIONS Gastrointestinal Irritation: Take with meals (5.1) ADVERSE REACTIONS Most common adverse reactions are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea.(6) TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT LUPIN PHARMACEUTICALS, INC. AT 1-800- 399-2561 OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH DRUG INTERACTIONS Triamterene and amiloride: Concomitant us Đọc toàn bộ tài liệu